Fate Therapeutics (FATE) News Today $1.09 +0.02 (+1.87%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.12 +0.03 (+3.21%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Q3 EPS Forecast for Fate Therapeutics Raised by AnalystAugust 17 at 9:27 AM | marketbeat.comQ3 EPS Estimate for Fate Therapeutics Boosted by AnalystAugust 17 at 2:47 AM | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Price Target Cut to $2.50 by Analysts at Wells Fargo & CompanyAugust 15 at 9:07 AM | marketbeat.comFate Therapeutics (NASDAQ:FATE) Issues Earnings ResultsAugust 14 at 5:26 PM | marketbeat.comFate Therapeutics Second Quarter 2025 Earnings: Beats ExpectationsAugust 14 at 8:44 AM | finance.yahoo.comFate Therapeutics price target lowered to $2.50 from $4 at Wells FargoAugust 13, 2025 | msn.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives $3.83 Consensus Target Price from AnalystsAugust 13, 2025 | americanbankingnews.comFate Therapeutics reports Q2 EPS (29c), consensus (34c)August 12, 2025 | msn.comFate Therapeutics Announces Corporate Restructuring PlanAugust 12, 2025 | msn.comFate Therapeutics: Q2 Earnings SnapshotAugust 12, 2025 | sfgate.comFate Therapeutics to Cut 12% of Workforce, 2Q Loss NarrowsAugust 12, 2025 | marketwatch.comFate Therapeutics Reports Second Quarter 2025 Financial Results and Business UpdatesAugust 12, 2025 | globenewswire.comWall Street Zen Downgrades Fate Therapeutics (NASDAQ:FATE) to SellAugust 12, 2025 | americanbankingnews.comFate Therapeutics (FATE) to Release Earnings on TuesdayAugust 11, 2025 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from BrokeragesAugust 11, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Rating Lowered to "Sell" at Wall Street ZenAugust 11, 2025 | marketbeat.comBahram Valamehr Sells 14,466 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) StockAugust 6, 2025 | marketbeat.comFate Therapeutics (FATE) Expected to Announce Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $15,333.96 in StockAugust 6, 2025 | insidertrades.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)August 5, 2025 | globenewswire.comFate Therapeutics (NASDAQ:FATE) Upgraded to "Hold" at Wall Street ZenAugust 3, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Monaco Asset Management SAMJuly 30, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from BrokeragesJuly 16, 2025 | marketbeat.comCould This Hawaii Community Be the Next Lahaina? Some Residents Fear a Similar Wildfire FateJuly 12, 2025 | msn.comFate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving Average - Here's What HappenedJuly 12, 2025 | marketbeat.comSmall Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth (ADIA, FATE, MESO, CRSP)July 9, 2025 | theglobeandmail.comResearch Analysts Offer Predictions for FATE Q2 EarningsJuly 4, 2025 | marketbeat.comRick Atkinson's 'The Fate of the Day' traces the middle years of the American RevolutionJuly 3, 2025 | yahoo.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comFate Therapeutics (NASDAQ:FATE) Downgraded to "Sell" Rating by Wall Street ZenJune 28, 2025 | marketbeat.comTMNT: Splintered Fate - Official Xbox Launch TrailerJune 26, 2025 | msn.comFate Therapeutics (NASDAQ:FATE) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell?June 20, 2025 | marketbeat.comFate Therapeutics’ SWOT analysis: promising data boosts stock outlookJune 15, 2025 | investing.comFate Therapeutics, Inc.: Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission ...June 13, 2025 | finanznachrichten.deFate Therapeutics price target lowered to $2.20 by BofA on SLE dataJune 13, 2025 | investing.comFate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025June 13, 2025 | nasdaq.comFate Therapeutics (NASDAQ:FATE) Receives "Hold" Rating from Needham & Company LLCJune 12, 2025 | marketbeat.comFate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 CongressJune 11, 2025 | globenewswire.comBank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)June 11, 2025 | marketbeat.comAnalysts Set Expectations for FATE FY2026 EarningsJune 10, 2025 | marketbeat.comAt Fate’s End, new game from Spiritfarer developers, revealedJune 9, 2025 | msn.comFate Therapeutics appoints new board memberJune 1, 2025 | investing.comFate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of DirectorsMay 30, 2025 | globenewswire.comFate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune DiseasesMay 28, 2025 | insidermonkey.comFate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 CongressMay 28, 2025 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by AnalystsMay 28, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Stock Holdings Trimmed by Woodline Partners LPMay 27, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Decreases Position in Fate Therapeutics, Inc. (NASDAQ:FATE)May 22, 2025 | marketbeat.comVestal Point Capital LP Increases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)May 21, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Holdings Raised by Tang Capital Management LLCMay 20, 2025 | marketbeat.com Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Media Mentions By Week FATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.370.64▲Average Medical News Sentiment FATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼223▲FATE Articles Average Week Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kodiak Sciences News Kamada News Erasca News Cullinan Therapeutics News COMPASS Pathways News Prothena News Tectonic Therapeutic News PureTech Health News CryoPort News Gossamer Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access